Kronik Astım Modelinde Farklı Nebulize Budezonid Doz Rejimleri

Year 2016, Volume: 17 Issue: 3, 138 - 145, 01.12.2016

Pınar Uysal Meral Karaman Tuba Tuncel Müge Kiray Nevin Uzuner Özkan Karaman

Abstract

-

Keywords

Astım, budezonid, tedavi, akciğer, kemik, fare

Different Nebulized Budesonide Dosing Regimens in a Mouse Model of Chronic Asthma

Abstract

Objective: The aim of this study was to compare the effectiveness of different inhaled steroid regimens on the lungs and their potential side effects on the bone tissues in chronic asthma model. Materials and Methods: Thirty-five specific pathogen-free BALB/c mice were divided into five groups. The mice in all of the study groups except the control group were sensitized with chicken egg albumin. After sensitization, the mice in group 2 were treated with saline modeling twice daily, the mice in group 3 were treated with 250 mcg of nebulized budesonide twice daily, the mice in group 4 were treated with 500 mcg of budesonide once daily, and the mice in group 5 were treated with 1000 mcg of budesonide every other day for the last 14 days of the challenge period. After challenge, the mice were sacrificed and lung and tibia samples were histologically examined. Results: Pulmonary parameters, including subepithelial smooth muscle thickness, goblet cell count, mast cell count and epithelial thickness, were the lowest in group 5 compared to other groups (p<0.01). Lung epithelial basement membrane thickness was the lowest in group 4 (p<0.01). In tibia bone tissue, there were no significant differences among treatment groups (group 3, 4 and 5) in terms of trabecular, cortical and osteoid thickness and number of trabeculae (p>0.01). Conclusion: The beneficial effect on lung tissue was highest in the treatment group receiving budesonide every other day (group 5) and no further measureable side effects on bone mineralization were observed in this group compared with the other treatment groups. Every-other-day treatment application seems to be the most effective regimen in chronic asthma model.

Keywords

Asthma, budesonide, treatment, lung, bone, mouse

References

• 1. Spahn J, Covar R, Stempel DA. Asthma: addressing consistency in results from basic science, clinical trials, and observational experience. J Allergy Clin Immunol 2002; 109(Suppl 5): S490- 502.
• 2. Masoli M, Fabian D, Holt S, Beasley R; Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469-78.
• 3. Kumar RK. Understanding airway wall remodeling in asthma: a basis for improvements in therapy? Pharmacol Ther 2001; 91: 93-104.
• 4. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368: 733-43.
• 5. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Götz M, et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008; 63: 5-34.
• 6. Meltzer EO, Pearlman DS, Eckerwall G, Uryniak T, DePietro M, Lampl K. Efficacy and safety of budesonide administered by pressurized metered-dose inhaler in children with asthma. Ann Allergy Asthma Immunol 2015; 115: 516-22.
• 7. Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar RK. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 1998; 53: 849-56.
• 8. Van den Bosch JM, Westermann CJ, Aumann J, Edsbäcker S, Tönnesson M, Selroos O. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos 1993; 14: 455-9.
• 9. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther 2003; 25: 28-41.
• 10. Jendbro M, Johansson CJ, Strandberg P, Falk-Nilsson H, Edsbäcker S. Pharmacokinetics of budesonide and its major ester metabolite after inhalation and intravenous administration of budesonide in the rat. Drug Metab Dispos 2001; 29: 769-76.
• 11. Edsbäcker S, Brattsand R. Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available data. Ann Allergy Asthma Immunol 2002; 88: 609-16.
• 12. Lexmüller K, Gullstrand H, Axelsson BO, Sjölin P, Korn SH, Silberstein DS, et al. Differences in endogenous esterification and retention in the rat trachea between budesonide and ciclesonide active metabolite. Drug Metab Dispos 2007; 35: 1788-96.
• 13. Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997; 25: 1311-7.
• 14. O’Connell EJ. Review of the unique properties of budesonide. Clin Ther 2003; 25(Suppl C): C42-60.
• 15. Mallol J, Aguirre V. Once versus twice daily budesonide metereddose inhaler in children with mild to moderate asthma: effect on symptoms and bronchial responsiveness. Allergol Immunopathol (Madr) 2007; 35: 25-31.
• 16. Masoli M, Weatherall M, Holt S, Beasley R. Budesonide once versus twice-daily administration: meta-analysis. Respirology 2004; 9: 528-34.
• 17. Weiner P, Weiner M, Azgad Y. Long term clinical comparison of single versus twice daily administration of inhaled budesonide in moderate asthma. Thorax 1995; 50: 1270-3.
• 18. Pandya D, Puttanna A, Balagopal V. Systemic effects of inhaled corticosteroids: an overview. Open Respir Med J 2014; 8: 59-65.
• 19. Gregson RK, Rao R, Murrills AJ, Taylor PA, Warner JO. Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Osteoporos Int 1998; 8: 418-22.
• 20. Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of Inhaled Corticosteroids on Growth in Children with Asthma: Systematic Review and Meta-Analysis. PLoS One 2015; 10: e0133428.
• 21. Silverman M, Sheffer AL, Díaz PV, Lindberg B. Safety and tolerability of inhaled budesonide in children in the Steroid Treatment As Regular Therapy in early asthma (START) trial. Pediatr Allergy Immunol 2006; 17(Suppl 17): 14-20.